{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "21996102",
  "DateCompleted": {
    "Year": "2012",
    "Month": "02",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2011",
        "Month": "10",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.ceb.2011.09.002"
    ],
    "Journal": {
      "ISSN": "1879-0410",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "6",
        "PubDate": {
          "Year": "2011",
          "Month": "Dec"
        }
      },
      "Title": "Current opinion in cell biology",
      "ISOAbbreviation": "Curr Opin Cell Biol"
    },
    "ArticleTitle": "Cell atrophy and loss in depression: reversal by antidepressant treatment.",
    "Pagination": {
      "StartPage": "730",
      "EndPage": "737",
      "MedlinePgn": "730-7"
    },
    "Abstract": {
      "AbstractText": [
        "Depression is associated with structural alterations in limbic brain regions that control emotion and mood. Studies of chronic stress in animal models and postmortem tissue from depressed subjects demonstrate that these structural alterations result from atrophy and loss of neurons and glial cells. These findings indicate that depression and stress-related mood disorders can be considered mild neurodegenerative disorders. Importantly, there is evidence that these structural alterations can be blocked or even reversed by elimination of stress and by antidepressant treatments. A major focus of current investigations is to characterize the molecular signaling pathways and factors that underlie these effects of stress, depression, and antidepressant treatment. Recent advances in this research area are discussed and potential novel targets for antidepressant development are highlighted."
      ],
      "CopyrightInformation": "Copyright \u00a9 2011 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Departments of Psychiatry and Neurobiology, Yale University School of Medicine, New Haven, CT 06508, United States."
          }
        ],
        "LastName": "Banasr",
        "ForeName": "Mounira",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Dwyer",
        "ForeName": "Jason M",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Duman",
        "ForeName": "Ronald S",
        "Initials": "RS"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 MH093897",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH093897-02",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH045481-14",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH093897-01",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH045481-15",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 MH045481",
        "Acronym": "MH",
        "Agency": "NIMH NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Curr Opin Cell Biol",
    "NlmUniqueID": "8913428",
    "ISSNLinking": "0955-0674"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Atrophy"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Brain"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Mood Disorders"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Neuroglia"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Neurons"
    }
  ]
}